Chinese Court Upholds Novo Nordisk’s Patent Rights
I'm PortAI, I can summarize articles.
China's Supreme People's Court has upheld Novo Nordisk's patent for semaglutide, reinforcing the company's intellectual property rights. CEO Mike Doustdar expressed that this ruling supports medical innovation and boosts confidence for foreign companies in China, encouraging the development of innovative medicines. The ruling does not alter previous communications about patent expirations or forecasts, and no financial details were provided.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments